{"nctId":"NCT00097786","briefTitle":"Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","startDateStruct":{"date":"2002-01"},"conditions":["Diabetes Mellitus, Type 2"],"count":9306,"armGroups":[{"label":"Valsartan 160 mg + nateglinide 60 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan 160 mg + nateglinide 60 mg"]},{"label":"Valsartan 160 mg + nateglinide placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan 160 mg + nateglinide placebo"]},{"label":"Nateglinide 60 mg + valsartan placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Nateglinide 60 mg + valsartan placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Valsartan placebo + nateglinide placebo"]}],"interventions":[{"name":"Valsartan 160 mg + nateglinide 60 mg","otherNames":[]},{"name":"Valsartan 160 mg + nateglinide placebo","otherNames":[]},{"name":"Nateglinide 60 mg + valsartan placebo","otherNames":[]},{"name":"Valsartan placebo + nateglinide placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults\n* Impaired glucose tolerance\n* Age dependent risk factors\n\nExclusion Criteria:\n\n* Frank diabetes\n\nFor detailed information, call contact person.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan","description":"Progression to diabetes was determined by (a) an algorithm based on central laboratory measurements of fasting plasma glucose and/or a 2 hour oral glucose tolerance test or (b) adjudication by the Diabetes Endpoint Adjudication Committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.1","spread":null},{"groupId":"OG001","value":"36.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan","description":"The extended cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularization procedure, hospitalization for congestive heart failure, and hospitalization for unstable angina.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan","description":"The core cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinide","description":"Progression to diabetes was determined by (a) an algorithm based on central laboratory measurements of fasting plasma glucose and/or a 2 hour oral glucose tolerance test or (b) adjudication by the Diabetes Endpoint Adjudication Committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":null},{"groupId":"OG001","value":"33.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide","description":"The extended cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularization procedure, hospitalization for congestive heart failure, and hospitalization for unstable angina.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide","description":"The core cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1031,"n":2297},"commonTop":["Hypotension","Nasopharyngitis","Dizziness","Arthralgia","Hypoglycaemia"]}}}